论文部分内容阅读
美国华盛顿消息:T肽是合成的蛋白质,能阻止人免疫缺损病毒(HIV)与细胞受体结合,在美国正在从实验室走向人体研究,虽然有些科学家抱有近乎蔑视的怀疑~1,断言这种化学药物没有作用。在斯德哥尔摩Karolinska研究所已经给4名艾滋病(AIDS)患者使用了这种肽~2,得到的临床效果说明有正当的理由在5月发起一项安慰剂对照临床试验,这项研究的指导者在华盛顿召开的第三届国际AIDS会议上作了报告。
Washington, DC, USA: T-peptide, a synthetic protein that blocks the binding of human immunodeficiency virus (HIV) to cellular receptors, is moving from the laboratory to human studies in the United States. Although some scientists harbor near contempt for suspicion, 1 it is asserted that Chemical drugs have no effect. The use of this peptide2 in four AIDS patients at the Karolinska Institute in Stockholm showed clinical justification for a justifiable reason to launch a placebo-controlled clinical trial in May. The mentor to the study was at Washington at the Third International AIDS Conference made a report.